Advantage Alpha Capital Partners LP Acquires Shares of 69,207 ImmunityBio, Inc. (NASDAQ:IBRX)

Advantage Alpha Capital Partners LP bought a new position in ImmunityBio, Inc. (NASDAQ:IBRX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 69,207 shares of the company’s stock, valued at approximately $257,000.

A number of other large investors have also modified their holdings of IBRX. Lazard Asset Management LLC lifted its position in ImmunityBio by 102.6% during the 1st quarter. Lazard Asset Management LLC now owns 13,019 shares of the company’s stock worth $68,000 after acquiring an additional 6,593 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of ImmunityBio by 1.6% during the first quarter. Vanguard Group Inc. now owns 13,539,590 shares of the company’s stock worth $72,708,000 after purchasing an additional 211,065 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of ImmunityBio by 37.9% in the second quarter. Bank of New York Mellon Corp now owns 621,536 shares of the company’s stock valued at $3,928,000 after purchasing an additional 170,742 shares during the period. DekaBank Deutsche Girozentrale grew its holdings in ImmunityBio by 4.5% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 205,092 shares of the company’s stock valued at $1,119,000 after purchasing an additional 8,892 shares in the last quarter. Finally, Private Advisor Group LLC increased its stake in ImmunityBio by 727.7% during the 2nd quarter. Private Advisor Group LLC now owns 86,907 shares of the company’s stock worth $549,000 after buying an additional 76,407 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Price Performance

Shares of IBRX stock opened at $5.12 on Wednesday. The firm has a fifty day moving average of $4.30 and a two-hundred day moving average of $5.12. ImmunityBio, Inc. has a 1-year low of $3.10 and a 1-year high of $10.53.

Analyst Ratings Changes

A number of research firms have weighed in on IBRX. D. Boral Capital reissued a “buy” rating and issued a $30.00 price objective on shares of ImmunityBio in a research report on Thursday, November 21st. Piper Sandler reduced their price target on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating for the company in a report on Monday, August 19th. Finally, EF Hutton Acquisition Co. I upgraded ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.